REG - GlaxoSmithKline PLC - Director/PDMR Shareholding <Origin Href="QuoteRef">GSK.L</Origin> - Part 1

GSKAnnouncement

16/10/2017 16:45

RNS Number : 7360T
GlaxoSmithKline PLC
16 October 2017
GlaxoSmithKline plc(the'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms E Walmsley
b)
Position/status
Chief Executive Officer
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
b)
Natureofthetransaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s)and 
volume(s)
Price(s)
Volume(s)
15.2750
1,605.036
15.2750
831.931
15.2750
2,740.030
15.2750
4,439.830
d)
Aggregatedinformation
AggregatedvolumePrice
9,616.827
15.2750
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr R G Connor
b)
Position/status
President, Global Manufacturing & Supply
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
b)
Natureofthetransaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s)and 
volume(s)
Price(s)
Volume(s)
15.2750
1,249.200
15.2750
1,600.015
15.2750
1,529.167
d)
Aggregatedinformation
AggregatedvolumePrice
4,378.382
15.2750
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr L Debruyne
b)
Position/status
President, Global Vaccines
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
b)
Natureofthetransaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s)and 
volume(s)
Price(s)
Volume(s)
15.2750
319.540
15.2750
402.745
15.2750
1,147.102
d)
Aggregatedinformation
AggregatedvolumePrice
1,869.387
15.2750
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr S Dingemans
b)
Position/status
Chief Financial Officer
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
b)
Natureofthetransaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s)and 
volume(s)
Price(s)
Volume(s)
15.2750
2,716.836
15.2750
2,942.442
15.2750
2,427.360
d)
Aggregatedinformation
AggregatedvolumePrice
8,086.638
15.2750
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr N Hirons
b)
Position/status
SVP, Global Ethics & Compliance
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
b)
Natureofthetransaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s)and 
volume(s)
Price(s)
Volume(s)
15.2750
605.675
15.2750
660.007
15.2750
563.370
d)
Aggregatedinformation
AggregatedvolumePrice
1,829.052
15.2750
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr B McNamara
b)
Position/status
CEO, GSK Consumer Healthcare
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Natureofthetransaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's 2009 Performance Share Plan.
c)
Price(s)and 
volume(s)
Price(s)
Volume(s)
$41.02
415.800
$41.02
83.187
$41.02
641.729
$41.02
1,036.064
d)
Aggregatedinformation
AggregatedvolumePrice
2,176.780
$41.02
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D S Redfern
b)
Position/status
Chief Strategy Officer
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
b)
Natureofthetransaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s)and 
volume(s)
Price(s)
Volume(s)
15.2750
993.680
15.2750
1,160.005
15.2750
1,094.561
d)
Aggregatedinformation
AggregatedvolumePrice
3,248.246
15.2750
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Ms C Thomas
b)
Position/status
SVP, HR
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
b)
Natureofthetransaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s)and 
volume(s)
Price(s)
Volume(s)
15.2750
1,324.911
15.2750
1,460.009
15.2750
1,207.230
d)
Aggregatedinformation
AggregatedvolumePrice
3,992.150
15.2750
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr P C Thomson
b)
Position/status
President, Global Affairs
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
b)
Natureofthetransaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s)and 
volume(s)
Price(s)
Volume(s)
15.2750
766.560
15.2750
840.010
15.2750
756.529
d)
Aggregatedinformation
AggregatedvolumePrice
2,363.099
15.2750
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mr D E Troy 
b)
Position/status
SVP & General Counsel
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
American Depositary Shares ('ADSs')
ISIN: US37733W1053
b)
Natureofthetransaction
Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 12 October 2017 on ADSs held in the Company's 2009 Performance Share Plan.
c)
Price(s)and 
volume(s)
Price(s)
Volume(s)
$41.02
1,132.956
$41.02
1,314.438
$41.02
1,154.472
d)
Aggregatedinformation
AggregatedvolumePrice
3,601.866
$41.02
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr P J T Vallance
b)
Position/status
President, R&D
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 
 
b)
Natureofthetransaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s)and 
volume(s)
Price(s)
Volume(s)
15.2750
2,755.819
15.2750
3,400.038
15.2750
3,138.824
d)
Aggregatedinformation
AggregatedvolumePrice
9,294.681
15.2750
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Mrs V A Whyte
b)
Position/status
Company Secretary
c)
Initial notification/
amendment
Initial notification
2. 
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name 
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Descriptionofthefinancial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Natureofthetransaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 12 October 2017 on Ordinary Shares held in the Company's 2009 Performance Share Plan.
c)
Price(s)and 
volume(s)
Price(s)
Volume(s)
15.2750
169.685
15.2750
160.363
15.2750
150.569
d)
Aggregatedinformation
AggregatedvolumePrice
480.617
15.2750
e)
Date ofthetransaction
2017-10-12
f)
Placeofthe transaction
n/a

This information is provided by RNS
The company news service from the London Stock Exchange
  END
DSHEQLFFDBFXFBX